Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients.
Giuseppe
G
Visani
Massimo
M
Breccia
Antonella
A
Gozzini
Giorgina
G
Specchia
Enrico
E
Montefusco
Enrica
E
Morra
Mario
M
Annunziata
Andrea
A
Camera
Francesco
F
Cavazzini
Fabio
F
Stagno
Patrizia
P
Pregno
Emilio
E
Usala
Valeria
V
Santini
Pier Paolo
PP
Piccaluga
Alessandro
A
Isidori
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001549:Benzamides; D000069439:Dasatinib; D004305:Dose-Response Relationship, Drug; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D007558:Italy; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D018365:Neoplasm, Residual / Q000175:diagnosis / Q000235:genetics; D010879:Piperazines / Q000493:pharmacokinetics; D011743:Pyrimidines / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000633:toxicity; D012074:Remission Induction; D012189:Retrospective Studies; D016019:Survival Analysis; D013844:Thiazoles / Q000008:administration & dosage* / Q000633:toxicity; D016896:Treatment Outcome; D055815:Young Adult
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D013844:Thiazoles; D000068877:Imatinib Mesylate; D000069439:Dasatinib